Corteva (NYSE:CTVA) Stock Price Expected to Rise, UBS Group Analyst Says

Key Points

• UBS raised its price target on Corteva from $80 to $88 while keeping a "neutral" rating—implying roughly a 5.2% upside—and the stock's consensus from 23 analysts is a Moderate Buy with an average target of $83.57.
• Corteva reported Q4 EPS of $0.22, meeting estimates but revenue of $3.91B missed the $4.23B consensus, and management set FY‑2026 guidance at $3.45–$3.70 EPS.
• Shares traded at $83.68 (near a 52‑week high of $85.63) with mid‑day volume below average; an insider (Brian Titus) sold 8,311 shares while institutional investors own about 81.5% of the company.

Corteva (NYSE:CTVA - Get Free Report) had its price objective increased by analysts at UBS Group from $80.00 to $88.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. UBS Group's target price points to a potential upside of 5.16% from the company's current price.

Several other equities analysts also recently issued reports on the stock. Wolfe Research upped their price objective on shares of Corteva from $81.00 to $86.00 and gave the company an "outperform" rating in a report on Thursday, February 5th. The Goldman Sachs Group reiterated a "buy" rating and issued a $88.00 target price on shares of Corteva in a research report on Thursday, February 5th. Wells Fargo & Company upped their target price on Corteva from $77.00 to $85.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. lowered Corteva from an "overweight" rating to a "neutral" rating and upped their target price for the company from $75.00 to $77.00 in a research report on Thursday, February 5th. Finally, Oppenheimer set a $86.00 target price on Corteva in a research report on Thursday, February 5th. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $83.57.

Corteva Stock Down 0.3%

Shares of CTVA traded down $0.28 during mid-day trading on Thursday, hitting $83.68. 3,468,157 shares of the company traded hands, compared to its average volume of 4,216,498. Corteva has a 1-year low of $56.14 and a 1-year high of $85.63. The company has a quick ratio of 0.96, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $56.18 billion, a PE ratio of 52.96, a price-to-earnings-growth ratio of 2.92 and a beta of 0.68. The business has a 50 day moving average of $78.32 and a 200 day moving average of $70.39.

Corteva (NYSE:CTVA - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the prior year, the company posted $0.32 earnings per share. The company's revenue for the quarter was down 1.7% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Equities research analysts anticipate that Corteva will post 2.96 EPS for the current year.

Insider Buying and Selling

In other Corteva news, insider Brian Titus sold 8,311 shares of the company's stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the sale, the insider owned 8,090 shares in the company, valued at approximately $619,289.50. This represents a 50.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.14% of the company's stock.

Institutional Investors Weigh In On Corteva

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Corteva by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 80,536,951 shares of the company's stock valued at $5,398,392,000 after buying an additional 317,538 shares in the last quarter. State Street Corp lifted its position in shares of Corteva by 3.7% during the 4th quarter. State Street Corp now owns 36,570,876 shares of the company's stock valued at $2,451,346,000 after buying an additional 1,290,071 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Corteva by 4.3% during the 4th quarter. Franklin Resources Inc. now owns 19,537,500 shares of the company's stock valued at $1,309,599,000 after buying an additional 805,873 shares in the last quarter. Harris Associates L P lifted its position in shares of Corteva by 168.1% during the 4th quarter. Harris Associates L P now owns 17,026,221 shares of the company's stock valued at $1,141,268,000 after buying an additional 10,675,052 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Corteva by 5.0% during the 4th quarter. Northern Trust Corp now owns 11,731,834 shares of the company's stock valued at $786,385,000 after buying an additional 562,550 shares in the last quarter. Hedge funds and other institutional investors own 81.54% of the company's stock.

Corteva Company Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.